Monte Rosa Therapeutics (GLUE) EBITDA (2020 - 2026)

Monte Rosa Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$50.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 213.62% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$148.3 million (down 6864.68% YoY), while the FY2025 annual figure was -$54.2 million, up 33.17% from the prior year.
• EBITDA for Q1 2026 stood at -$50.0 million, down from -$49.7 million in the prior quarter.
• The five-year high for EBITDA was $44.0 million in Q1 2025, with the low at -$50.0 million in Q1 2026.
• The 5-year median for EBITDA is -$32.6 million (2024), against an average of -$25.9 million.
• Peak annual rise in EBITDA reached 226.01% in 2025, while the deepest fall reached 482.31% in 2025.
• Monte Rosa Therapeutics' EBITDA stood at -$32.5 million in 2022, then retreated by 7.31% to -$34.9 million in 2023, then jumped by 137.3% to $13.0 million in 2024, then plunged by 482.31% to -$49.7 million in 2025, then retreated by 0.64% to -$50.0 million in 2026.
• Business Quant data shows GLUE's EBITDA at -$50.0 million in Q1 2026, -$49.7 million in Q4 2025, and -$33.0 million in Q3 2025.